Details for Patent: 8,691,507
✉ Email this page to a colleague
Which drugs does patent 8,691,507 protect, and when does it expire?
Patent 8,691,507 protects TAZVERIK and is included in one NDA.
This patent has sixty-four patent family members in sixteen countries.
Summary for Patent: 8,691,507
| Title: | Inhibitors of human EZH2 and methods of use thereof |
| Abstract: | The invention relates to determining the presence of an EZH2 gene mutation in a sample from a subject and inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono-through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject. |
| Inventor(s): | Copeland; Robert A. (Lexington, MA), Richon; Victoria M. (Wellesley, MA), Scott; Margaret D. (Beverly, MA), Sneeringer; Christopher J. (San Francisco, CA), Kuntz; Kevin W. (Woburn, MA), Knutson; Sarah K. (Cambridge, MA), Pollock; Roy M. (Medford, MA) |
| Assignee: | Epizyme, Inc. (Cambridge, MA) |
| Application Number: | 13/949,026 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,691,507
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,691,507
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011298987 | ⤷ Try a Trial | |||
| Australia | 2013232229 | ⤷ Try a Trial | |||
| Australia | 2017276284 | ⤷ Try a Trial | |||
| Australia | 2018201176 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
